NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities who purchased or otherwise acquired Verve Therapeutics, Inc. ("Verve" or the "Company") (NASDAQ: VERV) securities between August 9, 2022 and April 1, 2024, inclusive (the "Class Period"). The lawsuit seeks to recover damages for the Company's investors under the federal ...

ATLANTA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Verve Therapeutics, Inc. ("Verve Therapeutics" or "the Company") (NASDAQ: VERV). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company's business, operations, and prospects, including allegations that: (1) Defendants did not fully disclose the circumstances under which the Heart-1 trial would be halted; and (2 ...

NEW YORK, Aug. 8, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Verve Therapeutics, Inc. (NASDAQ: VERV) on behalf of the company's shareholders. The investigation seeks to determine whether Verve Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions. If you are a shareholder of Verve Therapeutics, Inc. and are interested in obtaining additional information regarding your rights and options, free of charge, please visit us at: h ...

Verve Therapeutics (VERV) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.87 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 13.24%. A quarter ago, it was expected that this biotechnology firm would post a loss of $0.68 per share when it actually produced a loss of $0.59, delivering a surprise of 13.24%. Over the last four quarters, the comp ...

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Verve is the subject of an article published by Bloomberg on April 2, 2024. According to the article, the Company "cited safety concerns for pausing enrollment in a study of its gene-editing treatment for people with high cholesterol, delivering a setback to the promising new field of medicine." Based on this news, shares of Verve fell by more than 40% in m ...

The employee received a stock option to purchase 76,900 shares of the company's common stock and 19,200 restricted stock units (RSUs). The option has an exercise price of $4.88 per share, which is equal to the closing price of the company's common stock on the date of grant. Such option has a 10-year term and will vest over a period of four years, with 25% of the shares vesting on the one-year anniversary of the grant date and the remainder vesting in equal monthly installments over the following three year ...

BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its board of directors. Dr. Tatsis currently serves as executive vice president, chief regulatory and quality officer, of Vertex Pharmaceuticals. Ms. Morrison currently serves as chief executive officer and director of Q32 Bio I ...

"We are thrilled to have Nia and Jodie join Verve's board of directors, lending their decades of impressive experience leading and advising pharmaceutical and biotech companies through critical stages in drug development, manufacturing, and commercialization," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve Therapeutics. "We look forward to their valuable insights as we focus on pipeline execution with the continued advancement of the Heart-2 clinical trial of VERVE-102 targetin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-40489 VERVE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 82-48001 ...

Exhibit 99.1 Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results First patient dosed in Heart-2 Phase 1b clinical trial of VERVE-102 VERVE-201 clinical trial initiation on track for the second half of 2024 Received first milestone payment from Eli Lilly for collaboration on an in vivo gene editing program targeting lipoprotein(a) (Lp(a)) Cash, cash equivalents and marketable securities of $606.4 million; cash runway into late 2026 BOSTON — May 8, 2024 — Verve Ther ...